(Q83131195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

invasive aspergillosis

1 reference

1

Johan Maertens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

6

Gregor Verhoef

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

8

Katrien Lagrou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Kristel Buvé

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Koen Theunissen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Wouter Meersseman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Eric Verbeken

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Johan Van Eldere

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

355-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Laboratory diagnosis of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Changes in causes of death over time after treatment for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Kappa coefficients in medical research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24022

7 January 2021

Identifiers

DOI

10.1002/CNCR.24022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19117035%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference